Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Estrogen esters as substrates for human paraoxonases.

Teiber JF, Billecke SS, La Du BN, Draganov DI.

Arch Biochem Biophys. 2007 May 1;461(1):24-9. Epub 2007 Mar 8.

PMID:
17412306
2.

Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.

Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN.

J Lipid Res. 2005 Jun;46(6):1239-47. Epub 2005 Mar 16.

3.

Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH.

Teiber JF, Draganov DI, La Du BN.

J Lipid Res. 2004 Dec;45(12):2260-8. Epub 2004 Sep 1.

4.

Pharmacogenetics of paraoxonases: a brief review.

Draganov DI, La Du BN.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):78-88. Epub 2003 Oct 25. Review.

5.

Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3.

Teiber JF, Draganov DI, La Du BN.

Biochem Pharmacol. 2003 Sep 15;66(6):887-96.

PMID:
12963475
6.

Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease.

La Du BN.

Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1317-8. No abstract available.

PMID:
12909569
7.

Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress.

Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN, Aviram M.

Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):468-74. Epub 2003 Jan 30.

PMID:
12615656
8.

Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine.

Ahmed Z, Babaei S, Maguire GF, Draganov D, Kuksis A, La Du BN, Connelly PW.

Cardiovasc Res. 2003 Jan;57(1):225-31.

PMID:
12504832
9.

Current progress on esterases: from molecular structure to function.

Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN.

Drug Metab Dispos. 2002 May;30(5):488-93.

PMID:
11950776
10.

Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite.

Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW.

Biochem Biophys Res Commun. 2002 Jan 11;290(1):391-6.

PMID:
11779181
11.

Baculovirus-mediated expression and purification of human serum paraoxonase 1A.

Brushia RJ, Forte TM, Oda MN, La Du BN, Bielicki JK.

J Lipid Res. 2001 Jun;42(6):951-8.

12.

Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor.

Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW.

J Biol Chem. 2001 Jul 6;276(27):24473-81. Epub 2001 Apr 24.

13.

Is paraoxonase-3 another hdl-associated protein protective against atherosclerosis?

La Du BN.

Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):467-8. No abstract available.

PMID:
11304457
14.

Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R.

Watson CE, Draganov DI, Billecke SS, Bisgaier CL, La Du BN.

Pharmacogenetics. 2001 Mar;11(2):123-34.

PMID:
11266077
15.

Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals.

La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA.

Drug Metab Dispos. 2001 Apr;29(4 Pt 2):566-9.

PMID:
11259353
16.

Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN.

Drug Metab Dispos. 2000 Nov;28(11):1335-42.

PMID:
11038162
17.

Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation.

Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN.

J Biol Chem. 2000 Oct 27;275(43):33435-42.

18.

Increased plasma cholinesterase activity and mivacurium resistance: report of a family.

Naguib M, Gomaa M, Samarkandi AH, Bevan DR, Akkielah AK, Watson C, Billecke S, La Du BN Jr.

Anesth Analg. 1999 Dec;89(6):1579-82. No abstract available.

PMID:
10589654
19.

Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.

Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN.

Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2214-25.

PMID:
10479665
20.

Recommended nomenclature system for the paraoxonases.

La Du BN, Furlong CE, Reiner E.

Chem Biol Interact. 1999 May 14;119-120:599-601. No abstract available.

PMID:
10421500
21.

On the physiological role(s) of the paraoxonases.

La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, Standiford TJ.

Chem Biol Interact. 1999 May 14;119-120:379-88. Review.

PMID:
10421474
22.

Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate.

Billecke SS, Primo-Parmo SL, Dunlop CS, Doorn JA, La Du BN, Broomfield CA.

Chem Biol Interact. 1999 May 14;119-120:251-6.

PMID:
10421459
23.

Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase.

Sorenson RC, Aviram M, Bisgaier CL, Billecke S, Hsu C, La Du BN.

Chem Biol Interact. 1999 May 14;119-120:243-9.

PMID:
10421458
24.

Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase.

Doorn JA, Sorenson RC, Billecke SS, Hsu C, La Du BN.

Chem Biol Interact. 1999 May 14;119-120:235-41.

PMID:
10421457
25.

Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans.

Haley RW, Billecke S, La Du BN.

Toxicol Appl Pharmacol. 1999 Jun 15;157(3):227-33.

PMID:
10373407
26.

High density associated enzymes: their role in vascular biology.

Navab M, Hama SY, Hough GP, Hedrick CC, Sorenson R, La Du BN, Kobashigawa JA, Fonarow GC, Berliner JA, Laks H, Fogelman AM.

Curr Opin Lipidol. 1998 Oct;9(5):449-56. Review.

PMID:
9812199
27.
28.

Are we ready to try to cure alkaptonuria?

La Du BN Jr.

Am J Hum Genet. 1998 Apr;62(4):765-7. Review. No abstract available.

29.

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN.

J Clin Invest. 1998 Apr 15;101(8):1581-90.

30.

Assessment of cassia gum.

Hallagan JB, La Du BN, Pariza MW, Putnam JM, Borzelleca JF.

Food Chem Toxicol. 1997 Jun;35(6):625-32. Review.

PMID:
9225022
31.

Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.

Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM, La Du BN.

J Clin Invest. 1997 Apr 15;99(8):2005-19. Erratum in: J Clin Invest 1997 Jun 15;99(12):3043.

32.

Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase.

Primo-Parmo SL, Lightstone H, La Du BN.

Pharmacogenetics. 1997 Feb;7(1):27-34.

PMID:
9110359
33.

Structural and functional diversity of paraoxonases.

La Du BN.

Nat Med. 1996 Nov;2(11):1186-7. No abstract available.

PMID:
8898738
34.

The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family.

Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN.

Genomics. 1996 May 1;33(3):498-507.

PMID:
8661009
35.

Evaluation of the safety of sodium pectate as a food ingredient.

Borzelleca JF, Filer LJ Jr, Kinoshita FK, Gerrish TC, Kuo PK, La Du BN.

Food Chem Toxicol. 1996 Jan;34(1):21-5. Review. Erratum in: Food Chem Toxicol 1996 Apr;34(4):432.

PMID:
8603793
36.

Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene.

Primo-Parmo SL, Bartels CF, Wiersema B, van der Spek AF, Innis JW, La Du BN.

Am J Hum Genet. 1996 Jan;58(1):52-64.

37.

The genetic mapping and gene structure of mouse paraoxonase/arylesterase.

Sorenson RC, Primo-Parmo SL, Camper SA, La Du BN.

Genomics. 1995 Dec 10;30(3):431-8.

PMID:
8825627
38.

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.

Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M.

J Clin Invest. 1995 Dec;96(6):2882-91.

39.

Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M.

J Clin Invest. 1995 Dec;96(6):2758-67.

40.

Comparison of purified human and rabbit serum paraoxonases.

Kuo CL, La Du BN.

Drug Metab Dispos. 1995 Sep;23(9):935-44.

PMID:
8565784
41.

Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase.

Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN.

Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7187-91.

42.

Prolonged response to succinylcholine: a new variant of plasma cholinesterase that is identified as normal by traditional phenotyping methods.

Greenberg CP, Primo-Parmo SL, Pantuck EJ, la Du BN.

Anesth Analg. 1995 Aug;81(2):419-21. No abstract available.

PMID:
7618741
43.

Butyrylcholinesterase variants and the new methods of molecular biology.

La Du BN.

Acta Anaesthesiol Scand. 1995 Feb;39(2):139-41. No abstract available.

PMID:
7793177
44.

Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2.

Pollak MR, Chou YH, Cerda JJ, Steinmann B, La Du BN, Seidman JG, Seidman CE.

Nat Genet. 1993 Oct;5(2):201-4.

PMID:
8252048
45.

Studies on human serum paraoxonase/arylesterase.

La Du BN, Adkins S, Kuo CL, Lipsig D.

Chem Biol Interact. 1993 Jun;87(1-3):25-34.

46.

The paraoxonase polymorphism in a Saudi Arabian population.

Nogueira CP, Evans DA, La Du BN.

Pharmacogenetics. 1993 Jun;3(3):144-9.

PMID:
8392888
48.

Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase.

Nogueira CP, Bartels CF, McGuire MC, Adkins S, Lubrano T, Rubinstein HM, Lightstone H, Van der Spek AF, Lockridge O, La Du BN.

Am J Hum Genet. 1992 Oct;51(4):821-8.

49.

Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families.

Jensen FS, Bartels CF, La Du BN.

Pharmacogenetics. 1992 Oct;2(5):234-40.

PMID:
1306123
50.

DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites.

Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, La Du BN.

Am J Hum Genet. 1992 May;50(5):1086-103.

Supplemental Content

Loading ...
Support Center